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Abstract
Background: The aim of this study is to evaluate the radiobiological impact of Acuros XB (AXB) vs. Anisotropic
Analytic Algorithm (AAA) dose calculation algorithms in combined dose-volume and biological optimized IMRT
plans of SBRT treatments for non-small-cell lung cancer (NSCLC) patients.
Methods: Twenty eight patients with NSCLC previously treated SBRT were re-planned using Varian Eclipse (V11) with
combined dose-volume and biological optimization IMRT sliding window technique. The total dose prescribed to the PTV
was 60 Gy with 12 Gy per fraction. The plans were initially optimized using AAA algorithm, and then were recomputed
using AXB using the same MUs and MLC files to compare with the dose distribution of the original plans and assess the
radiobiological as well as dosimetric impact of the two different dose algorithms. The Poisson Linear-Quadatric (PLQ) and
Lyman-Kutcher-Burman (LKB) models were used for estimating the tumor control probability (TCP) and normal tissue
complication probability (NTCP), respectively. The influence of the model parameter uncertainties on the TCP differences
and the NTCP differences between AAA and AXB plans were studied by applying different sets of published model
parameters. Patients were grouped into peripheral and centrally-located tumors to evaluate the impact of tumor location.
Results: PTV dose was lower in the re-calculated AXB plans, as compared to AAA plans. The median differences of
PTV(D95%) were 1.7 Gy (range: 0.3, 6.5 Gy) and 1.0 Gy (range: 0.6, 4.4 Gy) for peripheral tumors and centrally-located
tumors, respectively. The median differences of PTV(mean) were 0.4 Gy (range: 0.0, 1.9 Gy) and 0.9 Gy (range: 0.0,
4.3 Gy) for peripheral tumors and centrally-located tumors, respectively. TCP was also found lower in AXB-recalculated
plans compared with the AAA plans. The median (range) of the TCP differences for 30 month local control were 1.6 %
(0.3 %, 5.8 %) for peripheral tumors and 1.3 % (0.5 %, 3.4 %) for centrally located tumors. The lower TCP is associated with
the lower PTV coverage in AXB-recalculated plans. No obvious trend was observed between the calculation-resulted TCP
differences and tumor size or location. AAA and AXB yield very similar NTCP on lung pneumonitis according to the LKB
model estimation in the present study.
Conclusion: AAA apparently overestimates the PTV dose; the magnitude of resulting difference in calculated TCP was
up to 5.8 % in our study. AAA and AXB yield very similar NTCP on lung pneumonitis based on the LKB model parameter
sets we used in the present study.
Keywords: Combined dose-volume and biologically optimized IMRT, AAA and AXB dose calculation algorithms, TCP,
NTCP, Fractioned stereotactic radiotherapy, Non-small-cell lung cancer
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Introduction
The goal of radiation therapy is to optimize therapeutic
ratios by delivering tumoricidal doses to targets while
maximally sparing organs-at-risk (OARs). Mostly, the
quality of a radiation treatment plan is judged by isodose
distribution and dose-volume-histograms (DVH). Typic-
ally the biological outcomes in terms of tumor control
and normal tissue complication are not estimated when
evaluating a plan. Significant progress and contributions
to our understanding and modeling of volume effects
for both normal and tumor tissues started in the 1980s
with the advent of modern three dimensional treatment
planning techniques. Models for estimating the tumor
control probability(TCP) and normal-tissue complication
probabilities (NTCP) were proposed in the late 1980s
[1–8]. Even though dose-volume techniques are a main-
stay of current clinical treatment planning optimization,
biological optimization using complication probability
models in intensity modulated radiotherapy (IMRT) plan-
ning has shown potential for reducing radiation-induced
toxicity [9–11]. The current study used combined bio-
logical optimization and dose-volume optimization to take
advantage of using radiobiological models and at the same
time also keep the “important” dose-volume characteris-
tics. The report of AAPM Task Group 166 [12] recom-
mends that dose-volume constraints and the biologic
optimization function be used together for optimization.
In 2005, Eclipse TPS released the Analytical Aniso-
tropic Algorithm (AAA) [13]. AAA is a convolution–
superposition-based photon beam dose computation
algorithm. This algorithm was quickly and widely adopted
for clinical use. More recently, Varian Eclipse TPS imple-
mented another dose calculation algorithm, Acuros XB
Advanced Dose Calculation (AXB), which uses a deter-
ministic grid-based Boltzmann equation solver (GBBS
or the discrete ordinates method). The GBBS [14, 15]
explicitly solves the linear Boltzmann transport equation
(LBTE), which is the governing equation that describes
the macroscopic behavior of ionizing particles (neutrons,
photons, electrons, etc) as they travel through and interact
with matter. The GBBS then iteratively solves the radi-
ation transport problem within specified volumes to com-
pute radiation doses. AXB was first published by Vassiliev
et al. [16] and has been considered to be similar to classic
Monte Carlo methods for accurate modeling of dose
deposition in heterogeneous media [16–18].
Among the numerous studies comparing the dosimetric
differences between plans calculated with conventional al-
gorithms (pencil beam type and convolution-superposition
type) vs. with advanced algorithms (Monte Carlo type and
GBBS type) [19–26], lung SBRT has been shown as the
treatment where the differences due to dose algorithms
are among the most significant, hence necessitating the
adoption of the more advanced algorithms. This is due to
the low density lung tissue and the high risk of normal tis-
sue toxicity in hypofractionated treatments like SBRT.
Compared with the very large dosimetric differences
found between pencil beam type algorithms and ad-
vanced algorithms, smaller differences were seen between
convolution-superposition typealgorithms such as AAA
and advanced algorithms. Improved accuracy with ad-
vanced algorithms was always observed and deemed
necessary in some cases. Pertaining to the two dose
algorithms investigated, studies [19, 20] have illustrated
that AXB is more accurate in modelling the radiation
transportation and dose deposition in the patient. How-
ever, those studies were focused purely on dosimetric
comparisons between AAA and AXB algorithms. The im-
pact of these two algorithms on biological indices has not
been thoroughly studied. To date, the radiobiological im-
pact of AAA and AXB dose computation algorithms on
lung tumor treatment plans, where the impact of dose al-
gorithms would be prominent due to the low density lung
tissue, has not been published. Furthermore, planning
techniques in the existing literature investigating dosimetric
differences between the conventional and advanced dose
algorithms on lung SBRT were predominantly based on
physical dose volume constraints. In this paper, we have
retrospectively planned 28 stereotactic body radiation ther-
apy (SBRT) non-small-cell lung cancer (NSCLC) patients
using combined dose-volume optimization and biological
optimization provided by a Varian Eclipse (Varian Medical
Systems, Palo Alto, CA) planning system (V11). Dose com-
putation was performed alternatingly with AAA (V11) and
AXB (V11) algorithms on these plans optimized with AAA.
The tumor control probability (TCP) and normal tissue
complication probability (NTCP) on normal lung tissue
(pneumonitis ≥ 2) from AAA and AXB plans were evalu-
ated using the Eclipse biological evaluation module (V1.4).
Materials and methods
This study was approved by the University of
Arkansas Medical Science Institutional Review Board
(FWA00001119).
Treatment planning
Computed tomography (CT) data from 28 patients with
Stages I or II inoperable NSCLC previously treated using
SBRT were selected for this study. We have divided the
patients into two categories based on tumor location;
peripheral and centrally located. This distinction was
made due to the fact that the initial experience of SBRT
in inoperable lung cancer reported increased toxicity for
centrally located tumors [27]. A separate cooperative
trial was then designed to explore different fractionation
schemes for centrally located tumors [28]. Centrally
located tumors are those located either within 2 cm of
the airway (6 patients), or touch the pericardial pleura
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(2 patients), or adjacent to mediastinum (1 patient).
The rest of the tumors were considered peripheral
(19 patients). Patient characteristics are summarized
in Table 1. A four-dimensional computed tomography
(4DCT) was acquired for each patient. Maximum inten-
sity projection (MIP) and average intensity projection CTs
were reconstructed from the 4DCT. Internal target vol-
ume (ITV) was contoured using the MIP by one phys-
ician, and planning target volume (PTV) was generated by
applying a 0.5 cm isotropic margin to the ITV. Each
of the following structures was contoured using the
average intensity projection CT by the same physician
for every patient: bilateral lungs excluding ITV, spinal
cord, esophagus, and heart. A chest wall (CW) struc-
ture was also contoured as a 2 cm two-dimensional
expansion of the ipsilateral lung excluding the lung
volume and the mediastinal soft tissue as described
by Mutter et al [29]. The treatment planning was car-
ried out on the average intensity projection CT image
set. In order to obtain a conformal dose distribution,
two ring structures around the PTVwere also generated.
These rings are pseudo planning structures used in dose-
volume optimization to conform dose to the target and
reduce dose to normal tissue. Ring1 was defined as a 1 cm
width ring structure with a 4 mm gap to the PTV. Ring 2
was defined from outward of Ring1 to the body surface
and extended 3 cm superior/inferior to the PTV.
These 28 patients previously treated with SBRT were
retrospectively planned using Varian Eclipse TPS (V11)
with an IMRT sliding window technique. The total dose
prescribed to the PTV was 60 Gy with 12 Gy per frac-
tion. Plans were generated on each patient using 9 co-
planar 6 MV beams using a True Beam with an HD120
MLC (Varian Medical Systems, Palo Alto, CA). The
beam angles were chosen to best cover the PTV, while
maximally sparing lung and other critical structures.
The isocenter was placed at the center of the PTV. All
plans used combined dose-volume histogram and radio-
biological optimization to generate the optimal fluence
map. The starting dose-volume and biological optimization
cost function parameters used in the present study are
summarized in Tables 2 and 3. After the initial optimization
run, each plan was evaluated and fine-tuned by adjusting
the physical dose constraints according to the desired dose
distribution. After obtaining the optimized fluence map, the
MLC leaf motion and final dose to water were computed
using AAA. The treatment plan was normalized such that
95 % of the PTV is covered by the prescribed dose. The
plan was evaluated by the same physician in order to ascer-
tain that it met the institutional OAR dose constraints as
listed in Table 4. Finally the plan was recalculated using
AXB with dose to medium using the same MU and MLC
patterns. The calculation grid was set at 0.25 cm for both
AAA and AXB algorithms. A process flow diagram from
the CT acquisition to the final AAA- and AXB-calculated
plans is shown in Fig. 1.
TCP calculation
The Poisson Linear-Quadatric (PLQ) model was used
for estimating the tumor control probability. The PLQ
model [6] is derived from the linear-quadratic cell
survival model using the Poisson distribution:
Where ɣ is the normalized dose–response gradient,
D50 represents the dose yielding 50 % TCP for a given
end point, and EQD2 is the equivalent dose given in
2 Gy fractions and was calculated using equation 2 [30]:







Where D is the cumulative dose and d is the dose of a
single fraction.




Median age (range, yrs) 73 (60,88)
Tumor position, peripheral/central 19/9
Median PTV size (range, cc)
Peripheral 45.6 (15.3, 107.3)
Central 62.3 (19.0,144.9)
Table 2 Dose-volume cost function parameters used in this
study
Dose-volume cost function parameters
Structure Function type Physical Dose (Gy)
PTV Max Dose <63
Min Dose >60
Heart Max Dose <20
Spinal cord Max Dose <22
BilatLung-ITV D12% <20
Chest wall D13% <26
Esophagus Max Dose <30
D30% <24
Ring1 Max Dose <52.8
Ring2 Max Dose <30
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The TCP model parameter values were originally ob-
tained by fitting models on clinical data and are there-
fore dependent on various factors such as patient group,
type of treatment, and dose algorithm etc [31]. The
range of published D50 on lung treatment was fairly
large; Willner et al. [32] converted the total physical
dose to 2-Gy fractionation dose equivalent and reported
D50 Values of 74.5 Gy for 24 month local control and
Martel et al. [33] studied plans with 1.8 – 2.0 Gy per
fraction and reported D50 values of 72 and 84.5 Gy
for 24 and 30 month local control on NSCLC. While
Guckenberger et al. [34] reported a biologic effective dose
D50 of 42.3 Gy for 36 month local control. In the work of
Guckenberger et al., the patient population was primarily
pulmonary metastases. This may partially explain why in
their study, D50 was smaller than the D50’s reported by the
other groups [32, 33] where the studies were on NSCLC
patients. Therefore, the higher end of D50 range may be
more applicable to our NSCLC cohort. Table 5 summa-
rizes the TCP parameters that we used in the present
study. Here we made an approximation that the physical
dose of Martel et al. study is the same as EQD2 since
1.8 – 2 Gy per fraction was used in their study. After all
the treatment plans were computed with both AAA and
AXB, the plans were evaluated using the Eclipse biological
evaluation module (V1.4), where the DVHs were cor-
rected to 2-Gy fractionations according to the LQ
model. An α/β of 10Gy was used.
NTCP calculation
The Lyman-Kutcher-Burman (LKB) model was used
for estimating normal tissue complication probability
on lung pneumonitis. The LKB model is based on a
Probit function [1, 3–5]:










t ¼ EUD− D50
m : D50
ð4Þ
The parameter m and D50 represent the slope of the
sigmoid dose response curve and the dose for a compli-
cation rate of 50 %, respectively. EUD is the equivalent








Where vi is the partial volume with absorbed dose
EQD2,i and n is the dose-weighting factor, which defines
the risks associated with partial organ volume uniform
irradiation.
In the present study, the NTCP values for lung pneu-
monitis grade ≥ 2 were calculated using the LKB model.
Several studies have reported estimates of the model pa-
rameters obtained from different clinical studies. A study
from Burman et al. [4] was based on treatment plans
in which no density correction was performed. Later,
Seppenwoolde et al. [36] and Kwa et. al [37] presented dif-
ference model parameters obtained from density corrected
treatment plans. We applied these three sets of model pa-
rameters in this study to investigate the influence of the
model parameter uncertainty on NTCP. In addition, we
also studied the influence of α/β ratios by applying two
different α/β ratios for normal lung tissue; 1.3 Gy from
the recent study of Scheenstra et al. [38] and 3 Gy as the
standard normal tissue value.








Cord 30 N/A N/A
Heart 38 <15 cc 32
Esophagus 35 <5 cc 19.5
Bilateral Lung - ITV N/A 1000 cc 13.5
1500 cc 12.5
Table 3 Biological cost function parameters used in this study
Biological NTCP-LKB model parameters
Structure Endpoint D50 (Gy) α/β (Gy) n m References
BilatLung-ITV Pneumonit-is Grade≥ 2 30.8 1.3 0.99 0.37 [36, 38]
Esophagus Esophagitis Grade≥ 2 51.0 10 0.44 0.32 [50]
Heart Pericarditis 60.6 2.5 0.64 0.13 [51]
Biological NTCP-PLQ model parameters
Structure Endpoint D50 (Gy) α/β (Gy) ɣ s Reference
Spinal cord Myelitis necrosis 68.6 3 1.9 4.0 [52]
Esophagus Clinical Stricture 68.6 3 2.8 3.4 [52]
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Results and discussion
A comparison of the total physical dose DVHs of the
ITV, PTV and OARs for a typical patient plans calcu-
lated using the AAA and AXB dose algorithms is shown
in Fig. 2. Doses to PTV are generally higher in AAA-
calculated plans than AXB-recalculated plans, similar to
previous studies [24–26]. A comparison of total physical
dose to ITV and PTV calculated using AAA or AXB
dose algorithm for both peripheral tumor and centrally-
located tumor patients is given in Table 6. A non-
parametric Kruskal-Wallis test [39] was used to calculate
the p-value with p < 0.05 taken as significant. It appears
that lower doses to PTV (D95%) and PTV (mean) in the
re-calculated AXB plans, as compared to AAA plans.
The median differences of PTV (D95%) were 1.7 Gy
(range: 0.3, 6.5 Gy; p < <0.01) and 1.0 Gy (range: 0.6,
4.4 Gy; p < < 0.01) for peripheral tumor and centrally-
located tumor patients, respectively. The median differ-
ences of PTV (mean) were 0.4 Gy (range: 0.0 to 1.9 Gy;
P <0.05) and 0.9 Gy (range: 0.0, 4.3 Gy; P <0.05) for
patients with peripheral tumors and centrally-located
tumors respectively. As shown in Table 6, the difference
in the calculated mean dose to ITV is not statistically
significant. Here we need to note that our dose distribu-
tion was calculated on an average CT generated on a
4DCT scan. There are potential limitations on dose
calculation on a static CT of a moving target. On an
average CT, a significant fraction of the planning target
was represented by low density lung tissue to where the
optimizer tried to deliver a higher fluence in order to
achieve target dose coverage. Studies on lung SBRT
[40, 41] have shown that calculations on static CT under-
estimated the target dose, as compared to 4D calculations
where the dose was computed in a respiratory-correlated
CT.To keep the study consistent, the TCP parameters
used for analysis in the present study were also obtained
from non- respiratory-correlated CT plans.
To study the influence of different model parameters
on the calculated TCP difference between AAA and
AXB plans (ΔTCP), we have applied the Willner et al.
and Martel et al. parameter sets for 24 months local
control listed in Table 5. Very similar median ΔTCP for
24 months local control were found; for peripheral tu-
mors, 0.5 % (range: 0.1, 2.4 %) and 0.2 % (range: 0.0,
1.9 %), and for centrally-located tumors, 0.5 % (range:
0.2, 1.3 %) and 0.2 % (range: 0.1, 0.8 %) when using
Fig. 1 Process flow diagram from CT acquisition to final AAA and AXB plans








Willner et al. [32] 60 24 74.5 3.5
Martel et al. [33] 71 24 72.0 2.0
30 84.5 1.5
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Martel et al. and Willner et al. parameter sets, respect-
ively. Figure 3 shows the TCP values from both AAA
and AXB plans. The TCP values were found to be lower
in AXB-recalculated plans compared with those of
AAA-calculated plans. For 30 months local control, the
median ΔTCP were1.6 % (range: 0.3, 5.8 %) on periph-
eral tumor patients and 1.3 % (range: 0.5, 3.4 %) on
centrally-located tumor patients. The lower TCP values
from the AXB-recalculated plans are associated with a
lower PTV dose coverage which is mainly due to the dif-
ficulty of the AAA algorithm to properly manage the lat-
eral scattering in low-density media. Figure 4 shows the
TCP (30 month local control) differences between AAA
and AXB plans (ΔTCP) vs. the total physical dose differ-
ences of PTV (D95%) in the AAA and AXB plans
(ΔD95%). It clearly shows that ΔTCP increases as ΔD95%
increases. The TCP difference can be as large as 5.8 %
on the case with a 6.5 Gy total physical dose (EQD2
of 11.9 Gy) difference in D95%. Therefore, we recommend
using the most accurate dose calculation algorithm.
A smaller ΔTCP for 24 months local control was found
compared with ΔTCP for 30 month local control. This
may be because the median TCP values for 24 months
local control on both AAA and AXB plans were ap-
proaching 100 %, even in the AXB-recalculated plans
where the PTV dose coverage was lower than the
AAA-calculated plans. For peripheral tumors, 97.7 %
(range: 96.0, 98.5 %) and 99.6 % (range: 97.9, 99.8 %),
and for centrally located tumors, 98.0 % (range: 97.1,
98.7 %) and 99.5 % (range: 98.9, 99.8 %) when using
the Martel et al. and Willner et al. parameter set, respect-
ively. Therefore, no substantial ΔTCP can be observed
due to the slow slope of the TCP curve at this flat
region. While for 30 months local control, the TCP
values from AXB-recalculated plans were 87.1 %
(range: 83.6, 90.4 %) and 87.8 % (range: 85.0, 91.5 %)
for peripheral and centrally-located tumors, respectively.
With this level of TCP values, the TCP model was
able to show better discriminate between the dose
calculations algorithms.
Fig. 2 Total physics dose volume histogram of the PTV, ITV and OARs for a typical patient. Dose calculations were performed on an average
intensity CT, as generated form a 4D-CT
Table 6 Comparison of total physical doses totarget volume calculated using AAA and AXB for peripheral and centrally-located
tumor patients
Tumor location Target (dose metric) Median dose (range) in Gy P-values
AAA AXB
peripheral ITV (mean) 63.7 (62.3, 67.9) 63.9 (60.5, 68.1) 0.86
PTV (D95%) 60.0 (normalization) 58.3 (53.5,60.3) 4.66E-07
PTV (mean) 62.9 (61.7, 65.0) 62.2 (60.5, 64.5) 0.04
PTV (max) 66.0 (63.7, 73.2) 67.0 (64.1, 75.5) 0.19
PTV (min) 55.2 (51.2, 57.1) 51.3 (37.6, 56.1) 1.19E-05
Central ITV (mean) 64.7 (63.6, 73.1) 64.1 (61.1, 69.3) 0.31
PTV (D95%) 60.0 (normalization) 59.0 (55.6, 59.4) 1.00E-4
PTV (mean) 63.5 (62.8, 67.2) 62.6 (61.0, 66.0) 0.04
PTV (max) 66.9 (64.8, 86.9) 67.5 (63.9, 84.4) 0.83
PTV (min) 53.1 (45.1, 57.0) 50.4 (42.3, 53.6) 0.06
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Fig. 3 TCP calculated using Martal et al parameter set on PTV of AAA and AXB plans. a) and b) were calculated using the Willner et al. 24 months
local control parameters, c) and d) were calculated using the Martel et al. 24 months local control parameter set, and e) and f) were calculated using
the Martel et al. 30 months local control parameter set
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In addition, we also studied the relationship between
ΔTCP and the PTV size as well as the influence of tumor
location on ΔTCP. Figure 5 shows the ΔTCP (30 months
local control) vs. PTV size for both peripheral tumors and
centrally-located tumors, with no trend observed. Figure 6
shows the box plot of the ΔTCP (30 months local control)
comparison between peripheral tumors and centrally-
located tumors. The group with peripheral tumors shows
a slightly larger median ΔTCP (1.6 %), compared to the
group with centrally-located tumors (1.3 %). However, this
is not statistically significant with a p-value of 0.86. The
dose distribution on PTV depends on a complex set of
factors such as the beam angle, the location of tumors
relative to low density media in the beam path etc. We
have not observed obvious trends of ΔTCP with tumor
size and locations within the present study group.
The median and range of Lung pneumonitis NTCP of
AAA and AXB plans are listed in Table 7. The model
parameters used are also listed in Table 7. Unless other-
wise indicated an α/β of 1.3Gy [38] was used. AAA and
AXB plans yield very similar NTCP values for both per-
ipheral and centrally-located tumors. The median NTCP
and ΔNTCP values are slightly larger in the group with
centrally-located tumors, as compared to the group with
peripheral tumors. In centrally-located tumors, the critical
structures such as esophagus and heart are adjacent to the
PTV. In order to spare heart and esophagus, the plan
pushes more doses to the normal lung tissue in
centrally-located tumor cases. This translates into a
slightly sensitive change in NTCPs between the AAA and
AXB plans for the group with centrally-located tumors.
However, the NTCP difference between the centrally-
located tumor group and the peripheral tumor group is
not statistically significant (p-value of 0.40).
Figure 7 shows a box plot of the lung NTCP using
three different LKB model parameter sets on AXB-
recalculated treatment plans. The Burman et al. param-
eter set predicted the smallest NTCP, the Seppenwoolde
et al. parameter set predicted largest NTCP, while Kwa
et al. parameter set predicted between the other two par-
ameter sets. Interestingly, in two centrally-located tumor
cases, the Burman et al. parameter set predicted much
larger NTCP values compares to the other two param-
eter sets. That is because the Burman et al. parameter
set used a much sharper slope of the response curve
compared with the other two parameter sets, which re-
sults in a more dose-sensitive NTCP prediction. How-
ever, when we studied the influence of different model
parameter sets on the ΔNTCP, it did not change our
conclusion that AAA and AXB plans yield very similar
Fig. 4 ΔTCP (AAA-AXB) vs. PTV ΔD95%(AAA-AXB). Dose displayed
here are physical dose
Fig. 5 ΔTCP vs. PTV size using the Martel et al. 30 months local control
parameter set for both peripheral tumors and centrally-located tumors
Fig. 6 Box plot of ΔTCP comparison between peripheral tumors and
centrally-located tumors using the Martel et al. 30 months local control
parameter set. The red line represents the median NTCP and the black
bars represent the range of the data
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NTCP values. All the ΔNTCP remains <1 % except one
outlier, a centrally-located tumor patient with the largest
PTV size (144.9 cc), whose ΔNTCP was 5.4 % when
using the Burman et al. parameter set to calculate,while
values <1 % were obtained when using the other two
parameter sets. The small ΔNTCP might be because that
the NTCP models cannot discriminate between the dose
calculation algorithms at these low NTCP value regions.
We also studied the influence of α/β ratios using the
Seppenwoolde parameter set with the results also shown in
Table 7. Although the smaller α/β ratio (1.3 Gy) predicted
slightly larger lung NTCP compared to with the α/β of
3 Gy, again it showed a very minimal influence on ΔNTCP.
The mean lung dose (MLD) has been widely used as a
simple and effective metric for probability of pneumon-
itis [42]. In the present study, we have studied the rela-
tionship between the ΔNTCP and the MLD difference
between AAA and AXB plans (ΔMLD). No obvious
trend was observed. We also studied the correlation be-
tween the ΔNTCP and the PTV size with all three LKB
model parameter sets and with two different α/β ratios.
No correlation was observed.
Although we could not find published literature to
make direct comparisons against our current study on
SBRT lung plans, it is relevant to mention previous stud-
ies on the influence of dose calculation algorithms on
the predicted TCP and NTCP values [31, 43, 44], these
studies revealed some potential differences in TCP/
NTCP values depending on the calculation algorithm
used. Nielsen et al. [43] showed an estimated NTCP
value for pneumonitis that varied 4 % across the six in-
vestigated dose algorithms. Bufacchi et al. [44] reported
that the NTCP value from AAA-calculated plans was
lower than that from pencil beam-calculated plans in
most treated sites. Petillion et al. [31] reported lower
TCP and NTCP predictions when using advanced algo-
rithms. Since our fractionation scheme and studied algo-
rithms were much different from these published works,
direct comparison cannot be meaningfully made between
our findings and their results. The radiobiological indices
impact of AAA and ABX dose computation algorithms
were published by Rana et al. [45] and Padmanaban et al.
[46]. The study of Rana et al concluded that both
AAA and AXB predicted comparable NTCP and TCP
values for low-risk prostate cancer plans. However, in
Padmanaban et al. study on esophagus cancer, where it
also involves complex tissue heterogeneities, a difference
in TCP between 1.2 % and 3.1 % was found. The study of
Table 7 Median and range of NTCP on lungpneumonitis grade≥ 2 for peripheral and centrally-located tumor patients with three
different sets of LKB model parameters and two different α/β ratios
Median(range)%
AAA AXB (AAA-AXB) D50 (Gy) n m
Peripheral 0.7 (0.2, 5.3) 0.7 (0.1, 5.2) 0.01(-0.04,0.38) 30.5 1 0.3 Kwa [33]
Central 1.8 (0.2, 18.7) 1.7 (0.2, 18.5) 0.03(0.01,0.85)
Peripheral 2.5 (0.8, 6.0) 2.4 (0.8, 6.1) 0.04(-0.05,0.66) 30.8 0.99 0.37 Seppenwoolde [36] α/β = 1.3Gy [38]
Central 4.6 (0.9, 23.8) 4.4 (0.9, 23.6) 0.07(0.01,0.93)
Peripheral 2.1 (0.8, 5.8) 2.1 (0.7, 5.7) 0.03(-0.00,0.35) 30.8 0.99 0.37 Seppenwoolde [36] α/β = 3Gy
Central 3.1 (0.8, 13.9) 3.0 (0.8, 13.8) 0.04(0.01,0.47)
Peripheral 0.2 (0.0, 7.0) 0.2 (0.0, 15.9) 0.01(-0.12,1.10) 24.5 0.87 0.18 Burman [6]
Central 1.5 (0.0, 72.0) 1.2 (0.0, 71.2) 0.19(0.00,5.36)
Fig. 7 NTCP for lung pneumonitis grade≥ 2 calculated using the LKB model with three parameter sets. a peripheral tumors and b centrally
located tumors. The red line represents the median NTCP and the black bars represent the range of the data
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Petillion et al. [31] reported a 0.3 % lower TCP on breast
in AXB plans compared with AAA plans.
It should be stated that there are large uncertain-
ties in the biological models used and its associated
parameters.The published TCP/NTCP model parameters
that we used were obtained from studies that used different
treatment techniques and dose algorithms from the
present study. This would introduce some uncertainties
too. In addition, some studies have suggested that the LQ
model may overestimate the radiobiological effect at the
dose level commonly used in SBRT [47]. Conversely, re-
sults from our group and others suggests that the LQ
model may actually underestimate the cell killing expected
at higher SBRT doses if a significant amount of vascular
damage and indirect cell death occurs [48, 49]. Whatever
the case, it certainly seems appropriate to only treat the
findings of the current study as a relative comparison be-
tween the different dose calculation algorithms rather
than studying the absolute expected values. There is
likely a lot more biological information that could be
added to the model to make it more truly a biological
optimization and evaluation. As more clinical data are
collected, it may help in the formulation of methods to
predict biophysical response and result in more accurate
predictions of TCP and NTCP.
Conclusion
In this study, AXB-recalculated plans yielded lower TCP
than the AAA-calculated plans. The lower TCP is asso-
ciated with the lower PTV coverage in AXB-calculated
plans. The maximum 11.9 Gy EQD2 dose of ΔD95% in
our patient cohort corresponds to up to 5.8 % ΔTCP
for 30 months local control.AAA-calculated and AXB-
recalculated plans yield very similar NTCP values. The
above conclusion stays valid when different sets of
published lung NTCP model parameters were used. No
correlation was observed between the ΔTCP/ΔNTCP and
the PTV size or location.
Ethics approval and consent to participate
This study was approved by the University of





The authors declare that they have no competing interests.
Authors’ contributions
XL conceived of the study, participated in the design of the study, carried out
the studies and drafted the manuscript. JP conceived of the study, participated
in the design of the study, provided clinical expertise and helped to draft the
manuscript. DZ participated in the design of the study, data analysis and
helped to draft the manuscript. SM and XZ helped the analysis and drafting
of the manuscript, PC and RG helped in the radiobiological modelling and
drafting of the manuscript, EH and MH involved in the discussion and helped
the manuscript. VR involved in the discussion provided clinical expertise and
drafted the manuscript. All authors read and approved the final manuscript.
Acknowledgments
We acknowledge financial support by University of Nebraska Medical Center
for funding Open Access Publishing.
Author details
1Department of Radiation Oncology, University of Arkansas for Medical
Sciences, 4301 W. Markham St., #771, Little Rock, AR, USA. 2Department of
Radiation Oncology, University of Nebraska Medical Center, 42nd and Emile,
Omaha, NE, USA. 3Department of Radiation Oncology, University of Texas
MD Anderson Cancer Center, Houston, TX, USA.
Received: 15 May 2015 Accepted: 22 December 2015
References
1. Lyman JT. Complication probability as assessed from dose-volume
histograms. Radiat Res. 1985;104 Suppl. 8:S13–9.
2. Lyman JT, Wolbarst AB. Optimization of radiation therapy, III: A method of
assessing complication probabilities from dose-volume histograms. Int J
Radiat OncolBiol Phys. 1987;13:103–9.
3. Kutcher GJ, Burman C. Calculation of complication probability factors for
non-uniform normal tissue irradiation: the effective volume method. Int J
Radiat OncolBiol Phys. 1989;16:1623–30.
4. Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance
data to an analytic fuction. Int J Radiat Oncol Biol Phys. 1991;21(1):123–35.
5. Kutcher GJ, Burman C, Brewster L, Gotein M, Mohan R. Histogram reduction
method for Calculation complication probabilities for three dimensional
treatment evaluation. Int J Radiat Oncol Biol Phys. 1991;21(1):137–46.
6. Källman P, Agren A, Brahme A. Tumour and normal tissue responses to
fractionated non-uniform dose delivery. Int J Radiat Biol. 1992;62(2):249–62.
7. Schultheiss TE, Orten CG. Models in radiotherapy: definition of decision
criteria. Med Phys. 1985;12(2):183–7.
8. Morrill SM, Lane RG, Jacobson G, Rosen II. Treatment planning optimization
using constrained simulated annealing. Phys Med Biol. 1991;36(10):1341–61.
9. Qi XS, Semenenko VA, Li XA. Improved critical structure sparing with
biologically based IMRT optimization. Med Phys. 2009;36(5):1790–9.
10. Das S. A role for biological optimization within the current treatment
planning paradigm. Med Phys. 2009;36(10):4672–82.
11. Doit Q, Kavanagh B, Timmerman R, Miften M. Biological-based optimization
and volumetric modulated arc therapy delivery for stereotactic body
radiation therapy. Med Phys. 2012;39(1):237–45.
12. Allen Li X, Alber M, Deasy JO, Jackson A, Ken Jee KW, Marks LB, et al. The
use and QA of biologically related models for treatment planning: short
report of the TG-166 of the therapy physics committee of the AAPM. Med
Phys. 2012;39(3):1386–409.
13. Ulmer W, Pyyry J, Kaissl W. A 3D photon superposition/convolution
algorithm and its foundation on results of Monte Carlo calculations. Phys
Med Biol. 2005;50(8):1767–90.
14. Lewis EE, Miller WF. Computational Methods of Neutron Transport. New
York: Wiley; 1984.
15. Ahnesjö A, Aspradakis MM. Dose calculations for external photon beams in
radiotherapy. Phys Med Biol. 1999;44(11):R99–155.
16. Vassiliev ON, Wareing TA, McGhee J, Failla G, Salehpour MR, Mourtada F.
Validation of a new grid-based Boltzmann equation solver for dose calculation
in radiotherapy with photon beams. Phys Med Biol. 2010;55(3):581–98.
17. Bush K, Gagne IM, Zavgorodni S, Ansbacher W, Beckham W. Dosimetric
validation of Acuros XB with Monte Carlo methods for photon dose
calculations. Med Phys. 2011;38(4):2208–21.
18. Fogliata A, Nicolini G, Clivio A, Vanetti E, Mancosu P, Cozzi L. Dosimetric
validation of the Acuros XB Advanced Dose Calculation algorithm:
fundamental characterization in water. Phys Med Biol. 2011;56(6):1879–904.
19. Kan MW, Leung LH, Yu PK. Verification and dosimetric impact of Acuros XB
algorithm on intensity modulated stereotactic radiotherapy for locally
persistent nasopharyngeal carcinoma. Med Phys. 2012;39(8):4705–14.
20. Han T, Mikell JK, Salehpour M, Mourtada F. Dosimetric comparison of
Acuros XB deterministic radiation transport method with Monte Carlo and
Liang et al. Radiation Oncology  (2016) 11:10 Page 10 of 11
model-based convolution methods in heterogeneous media. Med Phys.
2011;38(5):2651–64.
21. Moiseenko V, Liu M, Bergman AM, Gill B, Kristensen S, Teke T, et al. Monte
Carlo calculation of dose distribution in early stage NSCLC patients planned
for accelerated hypofractionated radiation therapy in the NCIC-BR25
protocol. Phys Med Biol. 2010;55(3):723–33.
22. Elmpt WV, Ollers M, Velders M, Poels K, Mijnheer B, Ruysscher DD, et al.
Transition from a simple to a more advanced dose calculation algorithm for
radiotherapy of non-small cell lung cancer (NSCLC): implications for clinical
implementation in an individualized dose-escalation protocol. Radio Ther
Oncol. 2008;88(3):326–34.
23. Vanderstraeten B, Reynaert N, Paelinck L, Madani I, De Wagter C, De Gersem
W, et al. Accuracy of patient dose calculation for lung IMRT: A comparison
of Monte Carlo, convolution/superposition, and pencil beam computations.
Med Phys. 2006;33(9):3149–58.
24. Fogliata A, Nicolini G, Clivio A, Vanetti E, Cozzi L. Critical appraisal of Acuros
XB and Anisotropic Analytic Algorithm dose calculation in advanced non-small-
cell lung cancer treatments. Int J Radiat Oncol Biol Phys. 2012;83(5):1587–95.
25. Rana S, Rogers K, Pokharel S, Cheng C. Evaluation of Acuros XB algorithm
based on RTOG 0813 dosimetric criteria for SBRT lung treatment with
RapidArc. J Appl Clin Med Phys. 2014;15(1):4474.
26. Kroon PS, Hol S, Essers M. Dosimetric accuracy and clinical quality of Acuros
XB and AAA dose calculation algorithm for stereotactic and conventional
lung volumetric modulated arc therapy plans. Radiat Oncol. 2013;8:149.
27. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al.
Excessive toxicity when treating central tumors in a phase II study of
stereotactic body radiation therapy for medically inoperable early-stage
lung cancer. J Clin Oncol. 2006;24(30):4833–9.
28. Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early
Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically
Inoperable Patients. https://www.rtog.org/ClinicalTrials/ProtocolTable/
StudyDetails.aspx?study=0813. Accessed date: 6 Aug 2015.
29. Mutter RW, Liu F, Abreu A, Yorke E, Jackson A, Rosenzweig KE. Dose-volume
parameters predict for the development of chest wall pain after
stereotactic body radiation for lung cancer. Int J Radiat Oncol Biol Phys.
2012;82(5):1783–90.
30. Joiner MC, Bentzen SM. Time-dose relationships: the linear-quadratic
approach. In: Steel GG, editor. Basic clinical radiobiology. London: Edward
Arnold; 2002.
31. Petillion S, Swinnen A, Defraene G, Verhoeven K, Weltens C, Van den Heuvel F.
The photon dose calculation algorithm used in breast radiotherapy has
significant impact on the parameters of radiobiological models. J Appl Clin
Med Phys. 2014;15(4):4853.
32. Willner J, Baier K, Caragiani E, Tschammler A, Flentje M. Dose, volume, and
tumor control prediction in primary radiotherapy of non-small-cell lung
cancer. Int J Radiat Oncol Biol Phys. 2002;52(2):382–9.
33. Martel MK, Ten Haken RK, Hazuka MB, Kessler ML, Strawderman M, Turrisi AT,
et al. Estimation of tumor control probability model parameters from 3-D dose
distributions of non-small cell lung cancer patients. Lung Cancer. 1999;24(1):31–7.
34. Guckenberger M, Wulf J, Mueller G, Krieger T, Baier K, Gabor M, et al. Dose-
response relationship for image-guided stereotactic body radiotherapy of
pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol
Phys. 2009;74(1):47–54.
35. Niemierko A. A generalized concept of equivalent uniform dose (EUD). Med
Phys. 1999;26:1100.
36. Seppenwoolde Y, Lebesque JV, de Jaeger K, Belderbos JS, Boersma LJ,
Schilstra C, et al. Comparing different NTCP models that predict the
incidence of radiation pneumonitis. Normal tissue complication probability.
Int J Radiat Oncol Biol Phys. 2003;55(3):724–35.
37. Kwa SL, Lebesque JV, Theuws JC, Marks LB, Munley MT, Bentel G, et al.
Radiation pneumonitis as a function of mean lung dose: an analysis of
pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 1998;42(1):1–9.
38. Scheenstra AE, Rossi MM, Belderbos JS, Damen EM, Lebesque JV, Sonke JJ.
Alpha/beta ratio for normal lung tissue as estimated from lung cancer
patients treated with stereotactic body and conventionally fractionated
radiation therapy. Int J Radiat Oncol Biol Phys. 2014;88(1):224–8.
39. KruskalHK WWA. Use of ranks in one-criterion variance analysis. J Am Stat
Assoc. 1952;47(260):583–621.
40. Sikora M, Muzik J, Söhn M, Weinmann M, Alber M, Monte Carlo V. pencil beam
based optimization of stereotactic lung IMRT. Radiat Oncol. 2009;12(4):64.
41. Guckenberger M, Wilbert J, Krieger T, Richter A, Baier K, Meyer J, et al.
Four-dimensional treatment planning for stereotactic body radiotherapy.
Int J Radiat Oncol Biol Phys. 2007;69(1):276–85.
42. Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, et al.
Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys.
2010;76(3 Suppl):s70–6.
43. Nielsen TB, Wieslander E, Fogliata A, Nielsen M, Hansen O, Brink C. Influence
of dose calculation algorithms on the predicted dose distribution and NTCP
values for NSCLC patients. Med Phys. 2011;38(5):2412–8.
44. Bufacchi A, Nardiello B, Capparella R, Begnozzi L. Clinical implications in the
use of the PBC algorithm versus the AAA by comparison of different NTCP
models/parameters. Radiat Oncol. 2013;8(1):164.
45. Rana S, Rogers K. Radiobiological impact of Acuros XB dose calculation
algorithm on low-risk prostate cancer treatment plans created by RapidArc
technique. Austral-Asian J Cancer. 2012;11(4):261–9.
46. Padmanaban S, Warren S, Walsh A, Partridge M, Hawkins MA. Comparison
of Acuros (AXB) and Anisotropic Analytical Algorithm (AAA) for dose
calculation in treatment of oesophageal cancer: effects on modelling
tumour control probability. Radiat Oncol. 2014;9:286.
47. Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival curve
and single fraction equivalent dose: useful tools in understanding potency
of ablative radiotherapy. Int J Rad Onc Biol Phys. 2008;70(3):847–52.
48. Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW. Radiation-induced vascular damage
in tumors: implications of vascular damage in ablative hypofractionated
radiotherapy (SBRT and SRS). Radiat Res. 2012;177(3):311–27.
49. Song CW, Cho LC, Yuan J, Dusenbery KE, Griffin RJ, Levitt SH. Radiobiology
of stereotactic body radiation therapy/stereotactic radiosurgery and the
linear-quadratic model. Int J Radiat OncolBiol Phys. 2013;87(1):18–9.
50. Chapet O, Kong FM, Lee JS, Hayman JA, Ten Haken RK. Normal tissue
complication probability modeling for acute esophagitis in patients treated
with conformal radiation therapy for non-small cell lung cancer. Radiother
Oncol. 2005;77(2):176–81.
51. Martel MK, Sahijdak WM, Ten Haken RK, Kessler ML, Turrisi AT. Fraction size
and dose parameters related to the incidence of pericardial effusions. Int J
Radiat Oncol Biol Phys. 1998;40(1):155–61.
52. AgrenCronqvist AK, Källman P, Turesson I, Brahme A. Volume and heterogeneity
dependence of the dose-response relationship for head and neck tumours.
Acta Oncol. 1995;34(6):851–60.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Liang et al. Radiation Oncology  (2016) 11:10 Page 11 of 11
